ReviewCureus2026
A Review of Vulvovaginal Atrophy as Part of Genitourinary Syndrome of Menopause.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this narrative review, we evaluate and discuss current literature on the assessment of vulvovaginal atrophy as part of the genitourinary syndrome of menopause. Publications discussing clinical evaluation methods, including physical exam, cytology, pH, and symptom questionnaires, as well as laboratory evaluation through histology and genetic analysis, were reviewed. A wide variety of methods are used to clinically evaluate the signs and symptoms of atrophy; however, these tools lack consistency and validation across publications. We also appraised the pertinent publications evaluating the genetic changes in the vagina occurring with menopause and subsequent treatment. More research is needed to validate and standardize clinical evaluation techniques and to further define the genetic pathway alterations to develop targeted therapies in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.